Novan, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Morrisville NC United States (2006)
Status: Acquired by Ligand Pharmaceuticals (2023)

Organization Overview

First Clinical Trial
2011
NCT01556698
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Novan, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Berdazimer (10 trials)

nitric oxide (inomax) (4 trials)

Drugs in Phase 2 Trials (1)

nvn1000 (7 trials)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Condylomata Acuminata (Phase 2)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Eczema (Phase 1)

Molluscum Contagiosum (Phase 3)

Psoriasis (Phase 1)

Tinea (Phase 2)

Tinea Pedis (Phase 2)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 4